Century Therapeutics (IPSC) Shares Outstanding (Weighted Average) (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $193.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $193.5 million, up 124.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.5 million (up 124.92% YoY), and the FY2025 annual result was $86.6 million, up 10.05% from the prior year.
• Shares Outstanding (Weighted Average) grew to $193.5 million in Q1 2026 per IPSC's latest filing, from $86.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $193.5 million in Q1 2026 and troughed at $57.1 million in Q1 2022.
• A 5-year average of $76.1 million and a median of $62.3 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) soared 643.13% in 2022, then grew 2.11% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $57.8 million in 2022, then increased by 2.7% to $59.3 million in 2023, then surged by 32.6% to $78.6 million in 2024, then grew by 10.05% to $86.6 million in 2025, then surged by 123.52% to $193.5 million in 2026.
• Business Quant data shows IPSC's Shares Outstanding (Weighted Average) at $193.5 million in Q1 2026, $86.6 million in Q4 2025, and $86.3 million in Q3 2025.